Lundbeck Loses EU Appeal Over €146M 'Pay For Delay' Fine

Law360, London (March 25, 2021, 2:06 PM GMT) -- The European Union's top court has upheld €146 million ($172 million) in fines imposed on Danish pharmaceutical company Lundbeck and generic drug manufacturers for striking a "pay for delay" agreement over an antidepressant, finding on Thursday that the companies had violated competition law. 

Europe's highest court has upheld fines of €146 million ($172 million) imposed on a pharmaceutical company over a "pay for delay" agreement (Photo by Thomas Frey/picture alliance via Getty Images) The European Court of Justice rejected a handful of appeals challenging findings that Lundbeck violated EU law by paying drugmakers to delay generic versions of its citalopram antidepressant....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!